4.5 Interaction with other medicinal products and other forms of interaction  
 No interaction studies have been performed. In vitro tests showed that plerixafor was not metaboli sed by P450 CYP enzymes, did not inhibit or induce P450 CYP enzymes. Plerixafor did not act as a  substrate or inhibitor of P -glycoprotein in an in vitro study.  
 In clinical studies of patients with Non -Hodgkinâ€™s lymphoma, the addition of rituximab to a  mobilisation regimen of plerixafor and G -CSF did not impact patient safety or CD34+ cell yield.  
 
